A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Clinical trial NCT07513376 · RECRUITING

Trial details

NCT number: NCT07513376
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2026-05-04
Primary completion: 2034-08-22
Enrollment: 876

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.